An Update on the PARP Inhibitor Olaparib in mCRPC Patients: Review of the Phase 2 Results & A First Look at the Phase 3 Study.
Video Player is loading.
October 28, 2018
Noel Clarke shares a recent update in his work focused on the PARP inhibitor, olaparib for patients with castration-resistant prostate cancer (CRPC) in combination with abiraterone.
Biographies:
Noel W Clarke, Professor of Urologic Oncology, Director of the Genitourinary Research Group, Manchester University, Consultant Urologist at Salford Royal Hospital and The Christie, Manchester
Charles J. Ryan, MD
Biographies:
Noel W Clarke, Professor of Urologic Oncology, Director of the Genitourinary Research Group, Manchester University, Consultant Urologist at Salford Royal Hospital and The Christie, Manchester
Charles J. Ryan, MD
Related Content:
ASCO 2018: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Randomized Phase II Trial
Referenced in this discussion:
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomized, double-blind, placebo-controlled, phase 2 trial
ASCO 2018: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Randomized Phase II Trial
Referenced in this discussion:
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomized, double-blind, placebo-controlled, phase 2 trial